[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"child\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:child":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,43,72,107,131,179,207,234,262,292,327,351,377,405,437,461,487,511,544,572,596,618,643,674,704],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100645018","measuring-the-evolution-of-speech-perception-in-noise-in-realistic-sound-environments-according-to-age-100645018",false,"NCT07675941","Measuring the Evolution of Speech Perception in Noise, in Realistic Sound Environments According to Age","SI 360","Inclusion Criteria:\n\n* Children with normal hearing (average hearing thresholds at 250 Hz, 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz less than 20 dB)\n* Be between 7 and 15 years old\n* Be a native French speaker, without bilingualism\n* Have typical development, as assessed by a school level corresponding to their age;\n* No objection from at least one of the two legal guardians\n* Legal guardian registered with social security\n* Able to understand instructions and information provided\n\nExclusion Criteria:\n\n* Inability of the child to respond to tests\n* Abnormal hearing thresholds\n* Speech disorder treated by speech therapist\n* Inability to understand instructions \u002F to respond to tests\n* Neurological conditions\n* Multiple disabilities\n* Ongoing treatment that may affect alertness\n* Unstable ADHD\n* History of tympanic surgery for chronic otitis media\n* Legal impossibility",true,"ALL","7 Years","15 Years",{"count":22,"type":23},150,"ESTIMATED","OBSERVATIONAL","In clinical settings, hearing perception is typically assessed using audiometric tests administered in a controlled environment. To date, these tests are administered in silence or in the presence of noise from fixed sources at an arbitrarily predetermined signal-to-noise ratio. These assessment situations are not representative of the functional difficulties encountered by people with hearing loss or Auditory Processing Disorder in their daily lives. In real life, \"soundscapes\" are diverse. Hearing assessment and rehabilitation should include the child's everyday environments as well as their lifestyle habits.\n\nThe Immersion 360 System (Virtual reality system) was developed specifically to virtually reproduce complex everyday sound experiences with realistic noise types and sound presentation conditions, enabling the assessment of auditory perception under test conditions similar to those encountered in daily life. Some of the sound environments offered by this innovative system have been standardized for adults. No standards exist for children, and we have limited knowledge regarding the development of speech perception skills in noise during childhood and adolescence. It seems essential to measure the age-related development of speech perception in realistic sound environments in order to establish reference data for children and adolescents.\n\nThis work will, through functional assessments of the auditory system and linguistic tests (speech perception in noise), provide a better understanding of the functional development of the central auditory system for speech perception in noise. The results collected from normo-hearing individuals in the age groups of interest will provide a clinical baseline for comparison with patients of the same age.",[27,28,29],"Noise Exposure","Normal Hearing","Child","NOT_YET_RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":23},"2026-07",{"date":38,"type":23},"2027-07",{"name":40,"class":41},"University Hospital, Toulouse","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100642191","core-stability-functional-capacity-balance-strength-and-fatigue-in-pediatric-demyelinating-diseases-100642191","NCT07654738","Core Stability, Functional Capacity, Balance, Strength, and Fatigue in Pediatric Demyelinating Diseases","Investigation of the Relationship Between Core Stability, Functional Capacity, Balance, Lower Extremity Strength, and Fatigue in Pediatric Demyelinating Diseases","PEDI-CORE","Inclusion Criteria:\n\n* Age between 6 and 18 years\n* Diagnosed with a pediatric demyelinating disease\n* No relapse within the last 3 months\n* No botulinum toxin (Botox) injections within the last 3 months\n* No corticosteroid treatment within the last 3 months\n* Ability to read and write\n\nExclusion Criteria:\n\n* History of concomitant autoimmune diseases\n* Refusal of the patient and\u002For caregiver to participate in the study\n* History of another primary neurological disease\n* Cognitive impairment that limits understanding of instructions and participation in assessments\n* Visual and\u002For hearing impairments that interfere with activities of daily living\n* Presence of additional rheumatological conditions that may interfere with assessments\n* Spasticity grade ≥2 according to the Modified Ashworth Scale in any muscle group","6 Years","18 Years",{"count":54,"type":23},32,"This study aims to evaluate balance ability, core stability, functional capacity, lower extremity muscle strength, and fatigue levels in children diagnosed with central nervous system demyelinating diseases, in order to contribute to the development of evidence-based and individualized rehabilitation strategies.",[57,29,58,59,60],"Demyelinating Diseases of the Central Nervous System","Core Stability","Balance","Fatigue",[62,58,59,60],"Pediatric Demyelinating Diseases","2026-06-12",{"date":65,"type":34},"2026-06-17",{"date":67,"type":23},"2026-07-30",{"date":69,"type":23},"2028-01-30",{"name":71,"class":41},"Istanbul University - Cerrahpasa",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":24,"phases":4,"briefSummary":84,"conditions":85,"keywords":90,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":42},"100633151","comparison-of-two-airway-devices-i-gel-and-air-q-in-children-aged-1-10-years-during-general-anesthesia-100633151","NCT07522957","Comparison of Two Airway Devices (I-Gel and Air-Q) in Children Aged 1-10 Years During General Anesthesia","Effect of I-gel and Air-Q SP LMAs on Oropharyngeal Leak Pressure and Gastric Insufflation in Children: An Ultrasonography-Guided Randomized Study","Inclusion Criteria:\n\n* Children aged 1-10 years\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Scheduled for elective (non-emergency) surgery under general anesthesia\n* Planned use of a supraglottic airway device for airway management\n* Written informed consent obtained from a parent or legal guardian\n\nExclusion Criteria:\n\n* History of conditions associated with increased risk of aspiration (e.g., gastroesophageal reflux)\n* Known or predicted difficult airway (e.g., Mallampati score ≥ 3)\n* Congenital or acquired abnormalities of the face, neck, or upper airway\n* Active upper respiratory tract infection\n* Presence of significant pulmonary disease (e.g., asthma, bronchopulmonary dysplasia, cystic fibrosis)\n* Body mass index above the 95th percentile for age (morbid obesity)\n* Emergency surgery\n* Previous complications related to supraglottic airway device use\n* Failure of device placement or need to switch to an alternative airway management technique\n* Refusal of participation by parent or legal guardian","1 Year","10 Years",{"count":82,"type":23},60,"1 Day","This study aims to compare two commonly used airway devices (I-gel and Air-Q) in children aged 1-10 years undergoing general anesthesia for surgery. These devices help doctors keep the airway open and support breathing during the operation. The study will evaluate how well each device works, how easy they are to place, and whether they cause air to enter the stomach. Ultrasound will be used to safely check the position of the device and detect any air in the stomach. The results of this study may help improve the safety and effectiveness of airway management in children during anesthesia.",[86,87,88,89,29],"Anesthesia General","Ultrasonography","Laryngeal Mask Airways","Airway Management",[91,92,93,87,94,95],"Airway management","Laryngeal mask airway","Pediatric patients","Gastric insufflation","Supraglottic airway devices","RECRUITING","2026-04-21",{"date":99,"type":34},"2026-04-23",{"date":101,"type":23},"2026-04",{"date":103,"type":23},"2026-05",{"name":105,"class":106},"Ankara Etlik City Hospital","OTHER_GOV",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":52,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":42},"100406843","phase-4-pecs-study-for-cied-implantation-surgery-100406843","NCT04577690","PECS Study for CIED Implantation Surgery","Pectoral Nerve (PECS) Block for Cardiac Implantable Electronic Devices (CIED) Implantation Surgery","Inclusion Criteria:\n\n• All patients 3-18 years undergoing CIED surgery in the chest\n\nExclusion Criteria:\n\n* Children \\\u003C 3 years of age at time of procedure as bupivacaine is not licensed for this age group.\n* No parental or patient consent\n* Allergy to bupivacaine\n* Pregnancy or lactation\n* Any condition or diagnosis, that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk.","3 Years",{"count":116,"type":23},48,"INTERVENTIONAL",[119],"PHASE4","We aim to determine whether pectoral nerve block (PECS) performed after induction of anesthesia but before surgical incision results less opioid use in the post operative period compared with local infiltration alone in children undergoing Cardiac Implantable Electronic Device (CIED) surgery.",[122,29,123],"Pain, Postoperative","Adolescent",{"date":99,"type":34},{"date":126,"type":34},"2019-12-01",{"date":128,"type":23},"2028-01-01",{"name":130,"class":41},"The Hospital for Sick Children",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":117,"phases":141,"briefSummary":143,"conditions":144,"keywords":156,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":42},"100634199","time-to-healing-in-displaced-pediatric-diaphyseal-forearm-fractures-treated-with-bioabsorbable-compared-to-titanium-intramedullary-nails-100634199","NCT07536581","Time to Healing in Displaced Pediatric Diaphyseal Forearm Fractures Treated With Bioabsorbable Compared to Titanium Intramedullary Nails","Time to Healing in Displaced Pediatric Diaphyseal Forearm Fractures Treated With Bioabsorbable Compared to Titanium Intramedullary Nails: A Single-Center, Multi-Blinded, Randomized Parallel-Group, Non-Inferiority Study","FOREST","Inclusion Criteria:\n\n* Diagnosis of a traumatic diaphyseal forearm fracture of the radius, ulna, or both\n* Operative fixation required\n* Fractures must be complete (not unicortical or greenstick) AND displaced \\>50% of bone width (after attempted closed reduction) AND\u002FOR angulated \\>10° in any plane (after attempted closed reduction)\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Conditions where internal fixation is contraindicated (e.g. active or potential infection)\n* Grossly open fractures (Gustilo Anderson grade \\> 2)\n* Fracture occurred more than 2 weeks prior\n* Fractures that are well managed conservatively (undisplaced or minimally displaced)\n* Previous ipsilateral forearm fracture (risk of closed medullary canal)\n* Fractures unsuited for intramedullary nailing (e.g. multifragmentary, metaphyseal or epiphyseal)\n* Concurrent ipsilateral wrist or elbow involvement (e.g. Monteggia or Galeazzi variants)\n* Unable to participate in follow-up\n* Existing bone pathology (e.g. tumor, osteogenesis imperfecta, degenerative disease)\n* Participation in any other medical device or medicinal product study within the previous month that could influence in opinion of the PI the results of the present study\n\nIntraoperative exclusion criteria:\n\n* Fractures suitable for closed reduction and casting (see 6.3.9)\n* Indication for treatment 1 (BIN) only\n* Indication for treatment 2 (ESIN) only\n* Intraoperative decision to use implants other than the devices under investigation","13 Years",{"count":82,"type":23},[142],"NA","This study looks at children with forearm fractures that need surgery. The standard treatment uses titanium nails, which usually need to be removed in a second operation later. This study compares titanium nails with bioabsorbable nails, which gradually dissolve in the body and may help some children avoid another operation.\n\nThe study will compare how quickly the fractures heal on X-ray, and also look at complications, recovery, function, and the family's experience. Children who need surgery will be randomly assigned to one of the two treatments so the comparison is fair.\n\nHypothesis: The researchers expect that fractures treated with bioabsorbable nails will heal almost as quickly as fractures treated with titanium nails, while reducing the need for later implant removal surgery.",[145,146,147,148,29,123,149,150,151,152,153,154,155],"Forearm Injuries","Radius Fractures","Ulna Fractures","Fractures, Bone","Fracture Fixation, Intramedullary","Internal Fixation","Orthopedic Operations","Polymers","Fracture Healing","Radiography","Randomized Controlled Trial (RCT)",[155,157,158,159,160,161,162,163,164,165,166,167,168,169,170],"pediatric forearm fracture","forearm shaft fracture in children","elastic stable intramedullary nailingelastic stable intramedullary nailing","ESIN","titanium elastic nail","bioabsorbable intramedullary nail","TEN","BIN","radiographic healing","radiographic union","modified Radiographic Union Score","mRUS","non-inferiority trial","randomized trial","2026-04-17",{"date":173,"type":34},"2026-04-22",{"date":101,"type":23},{"date":176,"type":23},"2031-12",{"name":178,"class":41},"Children's Fractures Interest Group, Denmark",{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":17,"sex":18,"minAge":186,"maxAge":80,"enrollmentInfo":187,"targetDuration":4,"studyType":117,"phases":189,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":42},"100632148","mucoadhesive-gels-in-controlling-gag-reflex-among-children-during-dental-radiographic-examination-100632148","NCT07509918","Mucoadhesive Gels in Controlling Gag Reflex Among Children During Dental Radiographic Examination","Clinical Efficacy of Three Mucoadhesive Gels in Controlling Gag Reflex Among Children Aged 8-10 Years During Radiographic Examination:A Randomized Pilot Clinical Trial","Inclusion Criteria:\n\n* The study will include children aged between 8 and 10 years .\n* Pediatric dental patients requiring intraoral radiographs for diagnostic or treatment purposes will be recruited.\n* Children present with a fully erupted maxillary last molar to allow standardized placement of the radiographic film for gag reflex stimulation.\n* Written informed consent will be obtained from parents or legal guardians before participation.\n\nExclusion Criteria:\n\n* Children with systemic diseases or neurological disorders that may influence gag reflex,such as epilepsy or cerebral palsy.\n* Those with a history of allergies to the materials that will be used in the study gels are not considered eligible.\n* Patients with acute respiratory infections, oropharyngeal inflammation, or enlarged tonsils at the time of the examination are excluded to avoid confounding variables.\n* Children taking medications known to modify gag reflex or pulse rate, such as sedatives or antihistamines, are not included.\n* Uncooperative or extremely anxious children, classified as Frankl ratings 1 or 2, are excluded","8 Years",{"count":188,"type":23},66,[142],"This randomized clinical trial compares tannic acid-zinc acetate mucoadhesive gel with lidocaine gel for reducing gag reflex in children aged 8-10 years during radiographic dental examination Gag reflex severity and pulse rate will be assessed before and after gel application. The study evaluates the effectiveness of the tested gel as a potential alternative to lidocaine.",[192,29],"Gag Reflex",[194,195,196,197],"Gag reflex","Radiographic dental examination","Pediatric dentistry","Mucoadhesive gels","2026-04-02",{"date":200,"type":34},"2026-04-08",{"date":202,"type":23},"2026-09-01",{"date":204,"type":23},"2026-11-01",{"name":206,"class":41},"Cairo University",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":79,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":117,"phases":218,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":233},"100516090","phase-2-a-master-protocol-ly900023-that-includes-several-clinical-trials-of-drugs-for-children-and-young-adults-with-cancer-100516090","NCT05999994","A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research","CAMPFIRE","Inclusion Criteria:\n\nParticipants must meet all of the inclusion criteria below. Additional criteria are specified in the protocol amendment (individual addenda) to which the participant will enroll.\n\n* Have either measurable or evaluable disease using standard techniques by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).\n* The participant has a Lansky (\\\u003C16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50.\n* Participants must have discontinued all previous treatments for cancer or investigational agents greater than or equal to (≥)7 days after the last dose and must have recovered from clinically significant side effects.\n* The participant has adequate hematologic and organ function.\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to first dose.\n* Both female and male participants of childbearing potential must agree to use highly effective contraceptive precautions during the trial and for at least 3 months following the last dose of study drug.\n\nParticipants will be ineligible if they meet any of the exclusion criteria below. Additional criteria are specified in the protocol amendment to which the participant will enroll.\n\n* Participants with severe and\u002For uncontrolled concurrent medical disease or psychiatric illness\u002Fsocial situation that, in the opinion of the investigator, could cause unacceptable safety risks or compromise compliance with the protocol.\n* Participants who have active infections requiring therapy.\n* Participants who have had allogeneic bone marrow or solid organ transplant.\n* Participants who have had, or are planning to have, certain invasive procedures.\n* Female participants who are pregnant or breastfeeding.","39 Years",{"count":217,"type":23},105,[219],"PHASE2","The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug\u002Fdisease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.",[222,29,123],"Neoplasms","2026-03-26",{"date":225,"type":34},"2026-03-27",{"date":227,"type":34},"2020-01-22",{"date":229,"type":23},"2027-05",{"name":231,"class":232},"Eli Lilly and Company","INDUSTRY",73,{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":17,"sex":18,"minAge":114,"maxAge":51,"enrollmentInfo":241,"targetDuration":4,"studyType":117,"phases":243,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":42},"100629644","the-behavioral-effects-of-mindfulness-based-technology-use-training-in-preschool-children-100629644","NCT07477353","The Behavioral Effects of Mindfulness-Based Technology Use Training in Preschool Children","The Effect of Mindfulness-Based Technology Use Training Applied to Preschool Children on Media Use, Sleep, Fear, and Close Relationships","Inclusion Criteria:\n\n* Obtaining verbal and written parental consent\n\n  * Being in the 3-6-year-old preschool age range\n  * Agreeing to participate regularly in the mindfulness training program\n  * Being open to communication and group interaction during the training process\n  * Not having previously participated in a similar psychological resilience or emotion regulation program\n\nExclusion Criteria:\n\n* Refusing to participate in the study or withdrawing consent during the process\n\n  * Having a cognitive or physical impairment that would prevent the completion of the questionnaires\n  * Having a level of absenteeism that could affect the implementation of the study",{"count":242,"type":23},50,[142],"With the rapid advancement of technology, the use of digital devices has become widespread even in early childhood. While the conscious and controlled use of technology in the preschool period can contribute to children's development, prolonged and uncontrolled screen use can lead to various negative consequences such as sleep problems, attention issues, increased anxiety levels, and difficulties in social relationships. In particular, exposure to violent media content can cause children to perceive the world as more frightening and experience anxiety.\n\nMindfulness-based training supports individuals in directing their attention to the present moment, recognizing their emotions, and accepting their experiences without judgment. Such training is known to develop self-regulation, attention, and emotional awareness skills in children.\n\nThe purpose of this study is to examine the effect of mindfulness-based technology use training applied to preschool children on their media usage habits, sleep patterns, fear levels, and parent-child relationship. The study is planned as a randomized controlled trial with an experimental design. The intervention group will receive mindfulness-based technology use training, while the control group will receive no intervention. The study expects that mindfulness-based training will reduce children's screen time, improve sleep quality, decrease fear levels, and strengthen parent-child relationships. This study aims to contribute to the development of intervention programs that support healthy technology use in early childhood.",[29,246,247],"Mindfulness","Media Use",[249,250,251,252],"mindfulness-based education","fear reactions","sleep patterns","child","2026-03-17",{"date":255,"type":34},"2026-03-19",{"date":257,"type":23},"2026-03-15",{"date":259,"type":23},"2026-07-31",{"name":261,"class":41},"Yazgulu Hemedoglu",{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":18,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":117,"phases":273,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":42},"100559370","phase-2-brentuximab-vedotin-for-newly-diagnosed-chl-in-chinese-caya-based-on-petct-assessment-100559370","NCT06563245","Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET\u002FCT Assessment","A Phase II\u002FIII Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET\u002FCT Assessment","Inclusion Criteria:\n\n* Ages \\>=2\\~\\\u003C35 years at the time of enrollment;\n* Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;\n* Adequate organ function;\n* Patients and\u002For their parents or legal guardians sign a written informed consent;\n\nExclusion Criteria:\n\n* Patients with nodular lymphocyte-predominant HL;\n* Patients with an immunodeficiency that existed prior to diagnosis; such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible;Patients known to be positive for HIV are not eligible.\n* Patients who are pregnant; Lactating females who plan to breastfeed.\n* Patients who received systemic corticosteroids within 28 days of enrollment on this protocol","2 Years","35 Years",{"count":272,"type":23},96,[219,274],"PHASE3","Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.",[277,29,123,278,279,280,281,282,283],"Classical Hodgkin Lymphoma","Young Adult","Metabolic Response","Survival","Treatment","Brentuximab Vedotin","PET Scan",{"date":255,"type":34},{"date":286,"type":34},"2024-09-25",{"date":288,"type":23},"2039-11-15",{"name":290,"class":291},"Children's Cancer Group, China","NETWORK",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":52,"enrollmentInfo":300,"targetDuration":4,"studyType":117,"phases":302,"briefSummary":303,"conditions":304,"keywords":308,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":326},"100438477","clinical-effectiveness-of-the-picu-up-multifaceted-early-mobility-intervention-for-critically-ill-children-100438477","NCT04989790","Clinical Effectiveness of the \"PICU Up!\" Multifaceted Early Mobility Intervention for Critically Ill Children","Clinical Effectiveness of the \"PICU Up!\" Multifaceted Early Mobility Intervention for Critically Ill Children: A Pragmatic, Stepped-wedge Trial","PICU Up!","Inclusion Criteria:\n\n* Invasive mechanical ventilation via oral or nasal endotracheal tube ≥ 48 hours at 7 a.m. on PICU Day 3\n\nExclusion Criteria:\n\n* Active or anticipated withdrawal of life support within 48 hours\n* Open chest or open abdomen\n* Current use of Extracorporeal Membrane Oxygenation (ECMO)",{"count":301,"type":23},1440,[142],"While mortality in U.S. pediatric intensive care units (PICUs) is improving, surviving children frequently develop persistent physical, cognitive, and psychological impairments. Over half of critically ill children experience potentially preventable PICU-acquired morbidities, with mechanically ventilated children being at greatest risk. In critically ill adults, randomized trials have shown that progressive mobility, started early (within 3 days of initiating mechanical ventilation), decreases muscle weakness and the duration of mechanical ventilation. However, similar randomized studies have not been conducted in the PICU. The investigator's prior studies revealed that less than 10 percent of critically ill children at the highest risk of functional decline are evaluated by a physical or occupational therapist within 3 days of PICU admission. Given the interplay of sedation, delirium, sleep, and immobility in the PICU, single-component interventions, such as sedation protocolization, have not consistently shown benefit for decreasing mechanical ventilation duration. Thus, the investigators developed the first pediatric-specific, interprofessional intervention (PICU Up!) to integrate goal-directed sedation, delirium prevention, sleep promotion, and family engagement into daily PICU care in order to facilitate early and progressive mobility. The investigators have demonstrated the safety and feasibility of this pragmatic, multifaceted strategy in both single-site and multicenter pilot studies. Hence, the next phase of the investigators research is to evaluate the clinical effectiveness and delivery of the PICU Up! intervention across a range of PICU patients and health systems. The investigators propose a pragmatic, stepped-wedge, cluster randomized controlled trial that will include 10 academic and community hospitals in the United States, with the following Aims: 1) Evaluate if the PICU Up! intervention, delivered under real-world conditions, decreases mechanical ventilation duration (primary outcome) and improves delirium and functional status compared to usual care in critically ill children; and 2) Conduct a multi-stakeholder, mixed-methods process evaluation to identify key contextual factors associated with delivery of PICU Up!. If proven effective, the PICU Up! intervention has potential to profoundly change medical care in the PICU and substantially impact public health by improving outcomes for the growing number of pediatric survivors of critical illness.",[29,305,306,307],"Intensive Care Unit Acquired Weakness","Critical Illness","Hospital Acquired Pressure Ulcer",[309,310,311,312,313,314,315,316],"physical rehabilitation","post-intensive care syndrome","pediatric intensive care unit","sleep","sedation","delirium","physical therapy","occupational therapy","2026-03-16",{"date":319,"type":34},"2026-03-18",{"date":321,"type":34},"2022-08-08",{"date":323,"type":23},"2026-09-30",{"name":325,"class":41},"Johns Hopkins University",11,{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":350},"100504547","breaking-disparities-in-access-to-advanced-diabetes-technologies-in-children-with-type-1-diabetes-100504547","NCT05849753","Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes","Breaking Health Care Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes","Inclusion Criteria:\n\nDiagnosis of T1D for at least 1 year based on clinical presentation (polyuria, polydipsia, weight loss, and\u002For ketoacidosis, or with positive diabetes autoantibodies) on insulin, including injections or open-loop pumps\n\n* HbA1C ≥ 8.0% at least twice within the last 12 months before study initiation, upper limit of HbA1C \\\u003C14%\n* Be of lower SES, defined based on \\\u003C 200% above published US levels of poverty by family size and income, or based on exceptional circumstantial needs in the opinion of the investigators\n* Approximately 1\u002F3 AA, 1\u002F3 Hispanic\u002FLatinos, 1\u002F3 non-Hispanic whites. Asians, Pacific Islanders and other ethnic groups however will not be excluded from participation if other criteria met\n* History of hypothyroidism on adequate replacement therapy with normal thyroid function will be allowed\n\nExclusion Criteria:\n\n* Severe eczema or any other skin condition that would limit availability of healthy skin to wear devices\n* Chronic medications\u002Fmedical conditions that could interfere with diabetes management (ADHD medications allowed)\n* Chronic seizures, or severe neurodevelopmental delay\n* Current use of hybrid closed-loop, automated insulin delivery system\n* Significant mental health disorder that in opinion of the investigator would hinder device use","17 Years",{"count":242,"type":23},"50 children\u002Fadolescents (ages 6 to \\\u003C18yrs) with T1D in suboptimal control (HbA1c≥8.0%) and lower SES (below 200% poverty line) on insulin therapy (either injections or open-loop pumps) will be recruited at Nemours \\~ 1\u002F3 each AA, Hispanic\u002FLatino, non-Hispanic whites. All families that qualify and agree to transition to closed-loop technologies will be recruited to allow data to be gathered before and after use of devices. They will go through the process of approval with the assistance of an insurance navigator in clinic. Those not a CGM will be prescribed one as well. Diabetes care will be 'real life', devices will be prescribed, and care per clinic routine with periodic device downloads. Principal outcome, time-in-range, will be analyzed at 3-months compared to baseline, each participant their own control. Secondary outcomes including HbA1c, other glucose metrics and questionnaires related to use of technology and diabetes distress will be also analyzed. All outcomes will also be collected at 6-months. Results could have important and fast applicability to the field and help better inform decision makers, including payers, clinicians, and patients and families and could serve to decrease health care disparities in this needy population.",[338,29,339,340],"Diabetes Mellitus, Type 1","Delivery of Health Care","Equipment and Supplies","2026-02-19",{"date":343,"type":34},"2026-02-23",{"date":345,"type":34},"2023-07-26",{"date":347,"type":23},"2026-12-31",{"name":349,"class":41},"Nemours Children's Clinic",2,{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":17,"sex":18,"minAge":358,"maxAge":80,"enrollmentInfo":359,"targetDuration":4,"studyType":117,"phases":361,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":42},"100625883","the-effect-of-supporting-the-incision-site-with-toys-during-mobilization-in-children-aged-4-10-years-undergoing-abdominal-surgery-100625883","NCT07428421","The Effect of Supporting the Incision Site With Toys During Mobilization in Children Aged 4-10 Years Undergoing Abdominal Surgery","The Effect of Supporting the Incision Site With Toys During Mobilization on Pain and Fear Levels in Children Aged 4-10 Years Undergoing Abdominal Surgery","Inclusion Criteria:\n\n* Aged between 4 and 10 years\n* Having undergone abdominal surgery\n* Having undergone surgery under general anesthesia\n* Having received a single dose of analgesic (paracetamol) after surgery\n* Having undergone initial mobilization after surgery\n* Volunteering to participate in the study\n\nExclusion Criteria:\n\n* Previous surgical intervention\n* Major surgery\n* Chronic illness\n* The child has visual, hearing, and mental disabilities","4 Years",{"count":360,"type":23},74,[142],"Aim: The aim of this study is to determine the effect of supporting the wound area with a toy during mobilization on pain and fear in children undergoing abdominal surgery. Method: The study was a randomised controlled trial. The study sample consisted of 74 children (Toy: 37, control: 37) who has undergone abdominal surgery between March 2026 and December 2026 at the Mersin University Hospital Pediatric surgery department. The data collection tools used will be the Children Information Form, Wong Baker Pain Scale , Fear scale. In the intervention group, toy will be used after surgery, while the control group will receive routine care. The chils' pain and fear levels will be assessed by the nurse before and after the procedure.",[29],[365,366,367,368],"Abdominal Surgery","pediatric","nursing","toy","2026-02-16",{"date":343,"type":34},{"date":372,"type":23},"2026-03-01",{"date":374,"type":23},"2026-12-15",{"name":376,"class":41},"Tarsus University",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":17,"sex":18,"minAge":114,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":117,"phases":387,"briefSummary":388,"conditions":389,"keywords":395,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":4},"100618782","phase-3-melatonin-vs-midazolam-in-children-undergoing-tonsillectomy-100618782","NCT07336095","Melatonin vs Midazolam in Children Undergoing Tonsillectomy","Effect of Oral Melatonin Versus Oral Midazolam as a Premedication in Children Undergoing Tonsillectomy","Inclusion Criteria:\n\n-ALL children with ASA class I and class II\n\nExclusion Criteria:\n\n* chest infection\n* Abnormal mental milestones.\n* Children with any organ dysfunction.\n* Allergies to any of the drugs used.\n* Children with Obstructive sleep apnea.","12 Years",{"count":386,"type":23},195,[274],"Used as a premedication to decrease anxiety (Caumo et al., 2007). Midazolam, though has several drawbacks (McCann and Kain, 2001). Hence, an alternative premedication to midazolam will definitely have a widespread appeal.\n\nMelatonin is a hormone secreted by the pineal gland. Melatonin is different from benzodiazepines and their derivatives in that it exerts a promoting effect on sleep by amplifying day\u002Fnight differences in alertness and sleep quality and displaying a modest sleep-inducing effect, quite mild as compared to that seen with benzodiazepines (Ahmad et al., 2007). Melatonin has also been reported to cause preoperative anxiolysis and an increase in levels of sedation without impairing orientation (Naguib and Samarkandi, 2000). Hence, the aim of this study is to compare the effect of oral melatonin and oral midazolam on preoperative anxiety.\n\nEmergence delirium (ED) was first described in the literature in the early 1960s. Although often used interchangeably with emergence agitation, it is defined as a temporary dissociated state of consciousness after discontinuation of anesthesia. The characteristics that make up ED include irritability, inconsolable crying, distress and inability to cooperate (Reduque and Verghese, 2013).\n\nMidazolam is the most prescribed oral premedication in the preoperative setting. Its benefits include preoperative anxiolysis, amnesia, relatively rapid onset and short duration of action. Although most children have anxiolysis with midazolam, up to 29% may display a paradoxical agitation response (Shin et al., 2013).\n\nOral melatonin doses up to 0.4 mg\u002Fkg (maximum 20 mg) are effective in reducing ED in children (age 3-7 years) (Kain et al., 2009).\n\nAIM OF THE WORK The study aims to compare the effects of oral melatonin and oral midazolam on preoperative anxiety as a premedication in children undergoing tonsillectomy.",[390,29,391,392,393,394],"Emergence Delirium, Anesthesia","Anxiety","Midazolam Premedication","Melatonin Bioavailability","Tonsillectomy",[396],"melatonin, midazolam, anxiety, children, tonsillectomy","2026-01-02",{"date":399,"type":34},"2026-01-13",{"date":372,"type":23},{"date":402,"type":23},"2026-08",{"name":404,"class":41},"Ain Shams University",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":269,"maxAge":51,"enrollmentInfo":412,"targetDuration":4,"studyType":117,"phases":414,"briefSummary":415,"conditions":416,"keywords":422,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":42},"100523211","effect-of-fpca-on-incidence-of-emergency-delirium-in-children-after-surgery-100523211","NCT06092671","Effect of FPCA on Incidence of Emergency Delirium in Children After Surgery","Effect of Family-centred Perioperative Care for Anaesthesia on Incidence of Emergency Delirium in Children After Surgery: a Protocol for a Randomised Controlled Trial","Inclusion criteria:\n\n1. Children aged 2-6 years undergoing elective surgery with an estimated surgical duration of no longer than 2 hours;\n2. Receiving first general anaesthesia by inhalation, and American Society of Anaesthesiology (ASA) physical status I to II;\n3. A parent signed the informed consent form.\n\nExclusion criteria:\n\n1. Suffering important organ diseases;\n2. History of developmental retardation, neuropsychiatric diseases, psychological or cognitive impairment;\n3. History of severe hearing or visual impairment;\n4. Children are not suitable for inhalation anaesthesia considered by the researchers;\n5. The parent involving in this trial spends less than three months a year with the child;\n6. The parent is not competent for companionship considered by the researchers;\n7. Neither father nor mother is able to participate in the screening interview and the trial.",{"count":413,"type":23},444,[142],"Emergence delirium (ED) stands out as a prevalent postoperative complication among paediatric patients, correlating with extended hospitalization periods, escalated healthcare expenses, and increased incidence of postoperative maladaptive behaviours (POMBs). There is a lack of well-established pharmacological or non-pharmacological interventions demonstrating efficacy in reducing the occurrence of ED. Therefore, our objective is to assess the potential of family-centred perioperative care for anaesthesia (FPCA) in mitigating the incidence of ED in children, compared with routine anaesthesia.",[417,29,418,419,420,421],"Postoperative Complications","Family","Emergence Delirium","General Anaesthesia","Perioperative Care",[423,424,425,426,427],"perioperative care","emergency delirium","paediatric","general anaesthesia","postoperative maladaptive behaviours","2025-12-21",{"date":430,"type":34},"2025-12-29",{"date":432,"type":34},"2023-10-24",{"date":434,"type":23},"2026-12",{"name":436,"class":41},"Second Affiliated Hospital of Wenzhou Medical University",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":444,"maxAge":80,"enrollmentInfo":445,"targetDuration":4,"studyType":117,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":4},"100608604","preparing-kids-for-mri-using-vr-100608604","NCT07203716","Preparing Kids for MRI Using VR","Effect of Home-Based and Immediate Pre-Scan Virtual Reality Orientation on Motion Artifacts and Sedation Need in Pediatric MRI: A Three-Arm Randomized Controlled Trial","Inclusion Criteria:\n\n* Children 5 to 10 years old (inclusive).\n* First-ever MRI for a clinically indicated, non-emergent examination (outpatient or elective inpatient).\n* Ability to view the age-appropriate 360° VR module (head-mounted viewer or flat 360° on screen) with basic comprehension of instructions (child and\u002For caregiver in Turkish).\n* Parental\u002Fguardian informed consent and child assent per age\u002Fcompetence.\n* Standard MRI safety screening passed; institutional rescue sedation policies remain available if clinically required.\n\nExclusion Criteria:\n\n* MRI contraindications (e.g., non-MR-conditional implants, unsafe metallic foreign bodies).\n* Pre-planned sedation or general anesthesia irrespective of behavior (clinician decision made prior to randomization).\n* Conditions contraindicating VR exposure (e.g., uncontrolled epilepsy, severe motion sickness\u002Fvertigo causing intolerance).\n* Severe uncorrected visual or hearing impairment precluding module viewing or instruction adherence.\n* Emergent\u002Furgent MRI where study procedures could delay care.\n* Neurodevelopmental or behavioral conditions that render still positioning entirely unfeasible despite standard coaching (investigator judgment).\n* Prior participation in this trial (no re-enrollment).","5 Years",{"count":22,"type":23},[142],"Children frequently exhibit pre-MRI anxiety that can cause motion, repeated sequences, prolonged room time, and exposure to sedation. Orientation with Virtual Reality (VR) may reduce anxiety by familiarizing children with the scanner environment and expected sensations. This single-center, three-arm randomized clinical trial evaluates whether (1) Home+Booster VR (an age-appropriate 360° VR module at home \\~24-48 hours before MRI plus a brief on-site refresher immediately before positioning), (2) Pre-Scan VR only (same module viewed on site immediately before positioning), or (3) Usual Care without VR improves MRI image quality and tolerance in children undergoing their first-ever MRI.\n\nEligible participants are children scheduled for clinically indicated, non-emergent MRI with no prior MRI experience. Major exclusions comprise MRI contraindications; contraindications to VR use (e.g., uncontrolled epilepsy or severe motion sickness); uncorrected severe visual\u002Fhearing impairment precluding VR viewing; and inability to provide assent\u002Fconsent. After consent\u002Fassent, participants are randomized 1:1:1 to one of three arms. Anticipated enrollment is \\~150 total (\\~50 per arm; up to 60 per arm if feasible). All arms receive routine safety procedures and child-oriented coaching per institutional practice. The VR module (\\~8-10 minutes) provides a 360° walkthrough of the MRI process (sounds, positioning, keeping still) with child-focused narration. Adherence (timestamps\u002Fduration) is recorded where applicable.\n\nThe primary outcome is motion artifact rated on a predefined ordinal scale by a board-certified radiologist masked to allocation; the proportion achieving diagnostic quality without repeat\u002Fsedation is also reported. Key secondary outcomes include sedation requirement, number of repeated sequences, total scan room time, scan completion without interruption, and change in child anxiety (mYPAS-SF). Additional prespecified measures include comfort\u002Fcalmness Likert scales, Wong-Baker FACES pain, CEMS during scan, parent state anxiety, satisfaction VAS, physiologic vitals (heart rate, blood pressure, SpO₂) at defined peri-scan time points, observed crying and movement durations, and total scan duration. The trial uses parallel assignment with allocation concealment and masked outcome assessment. Analyses follow intention-to-treat with prespecified subgroup exploration by age bands (5-7 vs 8-10). Recruitment is planned for October 6, 2025; primary completion is expected within approximately three months.",[391,449,29,450,451],"Sedation","Virtual Reality","MRI","2025-10-01",{"date":454,"type":34},"2025-10-02",{"date":456,"type":23},"2025-10-06",{"date":458,"type":23},"2026-03-31",{"name":460,"class":41},"Haseki Training and Research Hospital",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":17,"sex":18,"minAge":80,"maxAge":334,"enrollmentInfo":468,"targetDuration":4,"studyType":117,"phases":469,"briefSummary":470,"conditions":471,"keywords":473,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":42},"100606934","exercise-as-medicine-for-pediatric-chronic-pain-100606934","NCT07182006","Exercise as Medicine for Pediatric Chronic Pain","Movement as Medicine: Can a Single Bout of Aerobic Exercise Elicit Exercise-induced Hypoalgesia in Youth With and Without Chronic Pain Syndromes?","Inclusion Criteria:\n\n* Primary or secondary chronic pain syndrome\n\nExclusion Criteria:\n\n* Allodynia (pain with light touch) at testing sites (non-dominant forearm)\n* Self-reported use of opioids in last week\n* Comorbid condition for which exercise is deemed unsafe by a physician or the (Physical Activity Readiness Questionnaire+) PARQ+\n* unable to safely ambulate on a treadmill",{"count":188,"type":23},[142],"Youth with chronic pain struggle to go to school, play sports, or spend time with friends and family due to pain. Medications are often ineffective, and aerobic exercise may improve both pain sensitivity and participation in valued life activities. This study will be the first to examine the impact of a single session of intense aerobic exercise on pain sensitivity measures in youth with and without chronic pain syndromes to help determine if aerobic exercise can improve pain and functioning.",[472,29,123],"Chronic Pain",[474,475,366,476,477],"aerobic exercise","chronic pain","quantitative sensory testing","endogenous pain modulation","2025-09-16",{"date":480,"type":34},"2025-09-19",{"date":482,"type":23},"2026-04-01",{"date":484,"type":23},"2027-03-30",{"name":486,"class":41},"Boston Children's Hospital",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":17,"sex":18,"minAge":444,"maxAge":139,"enrollmentInfo":494,"targetDuration":4,"studyType":117,"phases":495,"briefSummary":496,"conditions":497,"keywords":501,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":509,"locationsCount":42},"100605284","ai-toothbrush-and-visual-pedagogy-to-improve-oral-hygiene-in-children-with-autism-spectrum-disorder-100605284","NCT07160517","AI Toothbrush and Visual Pedagogy to Improve Oral Hygiene in Children With Autism Spectrum Disorder","Effectiveness of an Artificial Intelligence-Enabled Electric Toothbrush and Visual Pedagogy Materials on Oral Hygiene of Children With Autism Spectrum Disorder","Inclusion Criteria:Children aged 5-13 years with a prior diagnosis of autism spectrum disorder (ASD) level 1 , 2 or 3 confirmed by a neuropediatrician.\n\nChild must be accompanied by a primary caregiver (≥18 years old) responsible for daily oral hygiene.\n\nCaregiver must have access to a smartphone or computer to interact with the digital platform.\n\nWritten informed consent (TCLE) from the caregiver and assent (TALE) from the child.\n\n\\-\n\nExclusion Criteria:Severe systemic medical conditions that contraindicate participation in clinical oral evaluations.\n\nChildren with advanced periodontal disease or other oral conditions requiring urgent dental treatment.\n\nCaregivers who are unable or unwilling to use basic digital platforms (smartphone, tablet, or computer).\n\nFamilies who decline participation at any stage of the study.\n\n\\-",{"count":242,"type":23},[142],"This randomized clinical trial evaluates the effectiveness of an AI-enabled electric toothbrush and visual pedagogy materials in improving oral hygiene among children with autism spectrum disorder (ASD). The study compares plaque control, gingival health, and adherence between children using a manual toothbrush with visual pedagogy support and those using an AI-enabled electric toothbrush with app-based monitoring.",[498,29,499,500],"Autism Spectrum Disorder","Oral Health","Artificial Intelligence",[502],"Autism Spectrum Disorder, Toothbrushing, Oral Hygiene, Artificial Intelligence.","2025-08-29",{"date":505,"type":34},"2025-09-08",{"date":452,"type":23},{"date":508,"type":23},"2027-02-10",{"name":510,"class":41},"University of Sao Paulo",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":358,"maxAge":384,"enrollmentInfo":518,"targetDuration":4,"studyType":117,"phases":520,"briefSummary":521,"conditions":522,"keywords":525,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":542,"locationsCount":42},"100585316","oral-tacrolimus-vs-dexamethasone-micro-pulse-therapy-in-pediatric-rapidly-progressing-vitiligo-a-multicenter-rct-100585316","NCT06900777","Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT","Oral Tacrolimus Capsule Versus Dexamethasone Micro-pulse Therapy for the Treatment of Rapidly Progressing Vitiligo in Children: A Multicenter, Randomized, Controlled Study","Inclusion Criteria:\n\n* Children aged 4-12 years diagnosed with rapidly progressive non-segmental vitiligo (VIDA score ≥4, indicating disease progression within the past 6 weeks).\n\nTotal body surface area (BSA) affected by vitiligo between 1% and 50%. Guardians provide written informed consent for the child's participation.\n\nExclusion Criteria:\n\n* Stable-phase childhood vitiligo. Segmental, mucosal, undetermined, or generalized vitiligo. Systemic immunosuppressive therapy within the past 4 weeks. Known hypersensitivity to tacrolimus, other macrolide drugs, or study drug excipients.\n\nComorbidities precluding oral tacrolimus use (e.g., severe hepatic\u002Frenal dysfunction).\n\nObesity or systemic diseases (e.g., tuberculosis, acute\u002Fchronic infections, hypertension, congenital cardiovascular disease).\n\nAny condition deemed by investigators to increase participant risk or interfere with trial execution.",{"count":519,"type":23},90,[142],"This clinical study aims to compare the safety and effectiveness of two treatments-oral Tacrolimus capsules and Dexamethasone micro-pulse therapy-in children aged 4-12 years with rapidly progressing vitiligo. The study is a multicenter, randomized, controlled trial involving 90 participants, who will be divided equally into two groups. One group will receive daily Tacrolimus, while the other will take Dexamethasone on weekends. Over 24 weeks, doctors will monitor improvements in skin repigmentation, side effects, and overall health through regular check-ups and blood tests. The goal is to determine which treatment better controls disease progression and improves quality of life for children with vitiligo.\n\nKey Points:\n\n* For children with rapidly spreading vitiligo.\n* Compares two common medications.\n* Follows participants for 6 months.\n* Focuses on safety and effectiveness.",[523,29,524],"Vitiligo","Progressive Disease",[526,527,528,529,523,530,531,532,533,534,535],"Tacrolimus","Dexamethasone","Randomized Controlled Trialy","Children","Safety","Efficacy","Multicenter Study","VASI Score","IGA Score","Immunosuppressive Therapy","2025-06-16",{"date":538,"type":34},"2025-06-19",{"date":540,"type":34},"2025-04-01",{"date":482,"type":23},{"name":543,"class":41},"Xijing Hospital",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":18,"minAge":186,"maxAge":52,"enrollmentInfo":551,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":552,"conditions":553,"keywords":556,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":42},"100500017","vascular-complications-in-children-from-t1d-diagnosis-100500017","NCT05790785","Vascular Complications in Children From T1D Diagnosis","Understanding Vascular Complications in Children From Type 1 Diabetes Diagnosis","Inclusion Criteria\n\n1. Between the ages of 8-18 years\n2. Within 14 weeks of type 1 diabetes diagnosis\n3. Ability and willingness to undergo non-invasive arterial stiffness assessment for 1hr and willingness to wear the 24-h automated blood pressure monitoring (ABPM) device.\n\nExclusion Criteria\n\nChildren will be ineligible to participate in the study if they meet any of the following:\n\n1. Other cardiometabolic or endocrine diseases diagnosis (type 2 diabetes; familial disorders of cholesterol metabolism; lupus)\n2. Other genetic syndromes (Down Syndrome; Prader-Willi)\n3. Eating disorder diagnosis\n4. Transgender children taking hormone blockers or exogenous sex steroids\n5. Currently treated with medications known to affect metabolism (e.g. glucocorticoids, antipsychotics).",{"count":22,"type":23},"Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from T1D diagnosis.",[554,555,29,123],"Type 1 Diabetes","Cardiovascular Complications",[557,529,558,559,560,561,562],"Type 1 diabetes","Arterial stiffness","Body composition","Biomarkers","Nutrition","Blood pressure","2025-04-29",{"date":565,"type":34},"2025-05-02",{"date":567,"type":34},"2024-03-25",{"date":569,"type":23},"2027-09-30",{"name":571,"class":41},"University of British Columbia",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":18,"minAge":579,"maxAge":52,"enrollmentInfo":580,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":582,"conditions":583,"keywords":585,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":4},"100403093","a-study-of-child-injury-based-on-data-mining-100403093","NCT04528810","A Study of Child Injury Based on Data Mining","A Prospective Observational Study of Child Injury Based on Data Mining","Inclusion Criteria:\n\nAll pediatric patients between the ages of 0-18 years newly diagnosed with injuries in the emergency department，and recorded ICD-10 diagnosis codes from V01 to X39\n\nExclusion Criteria:\n\nPatients who were dead on arrival to the emergency department are not included.","0 Years",{"count":581,"type":23},10762,"A comprehensive pediatric injury burden assessment is an essential foundation for formulating injury prevention strategies and improving emergency care for injured children. Although the hospital-based passive surveillance of national injury surveillance system of medical and health institutions has been well-established in China, the monitoring points of hospitals were not stratified according to children's hospital. Aim of the project is to collect epidemiological and clinical data to describe causes, clinical features and outcomes of pediatric injuries at a Children's Hospital in Shanghai, China. The project intends to establish a method for collecting and analyzing high quality data of child injury using data mining based on the hospital information system.",[584,29],"Injuries",[584,29,586],"Epidemiology","2025-02-16",{"date":589,"type":34},"2025-02-18",{"date":591,"type":23},"2025-07-01",{"date":593,"type":23},"2027-07-31",{"name":595,"class":41},"Children's Hospital of Fudan University",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":602,"maxAge":186,"enrollmentInfo":603,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":605,"conditions":606,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":42},"100318502","correlation-between-sedation-depth-monitoring-and-reflexes-during-intravenous-anesthesia-with-dexmedetomidine-and-remifentanil-in-children-undergoing-direct-laryngoscopy-for-surgical-procedures-100318502","NCT03426579","Correlation Between Sedation Depth Monitoring and Reflexes During Intravenous Anesthesia With Dexmedetomidine and Remifentanil in Children Undergoing Direct Laryngoscopy for Surgical Procedures","Inclusion Criteria:\n\nscheduled for elective direct laryngoscopy with surgical intervention, written informed consent of their parents or legal guardian.\n\nExclusion Criteria:\n\nrefusal of informed consent, known allergy for dexmedetomidine or remifentanil at start of anesthesia pulse oxygen saturation (SaO2) lower than 85%","1 Month",{"count":604,"type":23},10,"This study evaluates the correlation between sedation depth monitoring obtained by NeuroSENSE ® NS 701 Monitor and reflexes during intravenous anesthesia in children undergoing direct laryngoscopy for surgical procedures.",[607,29,608],"Laryngoscopy","Monitoring","2025-01-20",{"date":611,"type":34},"2025-01-22",{"date":613,"type":34},"2017-10-23",{"date":615,"type":23},"2025-12-31",{"name":617,"class":41},"University Hospital, Antwerp",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":18,"minAge":624,"maxAge":384,"enrollmentInfo":625,"targetDuration":4,"studyType":117,"phases":626,"briefSummary":627,"conditions":628,"keywords":633,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":42},"100576937","the-effect-of-aromatherapy-applied-to-children-aged-9-12-on-exam-anxiety-attention-deficit-and-academic-success-100576937","NCT06791785","The Effect Of Aromatherapy Applied To Children Aged 9-12 On Exam Anxiety, Attention Deficit and Academic Success","Inclusion Criteria:\n\n* Must be between the ages of 9-12\n* Must have family permission to participate in the study\n* Must have children who can give consent to participate in the study\n\nExclusion Criteria:\n\n* Having a chronic disease related to the respiratory system\n* Being allergic to lemon or lavender aroma\n* Being a child with special needs\n* Being included in an Individualized Education Program (IEP)\n* Developing any problems during the application","9 Years",{"count":188,"type":23},[142],"This study was planned to examine the effects of aromatherapy applied to children aged 9-12 on exam anxiety, attention deficit and academic success. The study was conducted as single blind.\n\nHypotheses of the Study H1: Children given lemon aroma with an aromatherapy diffuser have higher Burdon Attention Test mean scores than children in the placebo group; H1.1. Burdon Attention Test mean scores are higher. H1.2. Westside Exam Anxiety mean scores are lower. H2: Children given lavender aroma with an aromatherapy diffuser have higher Burdon Attention Test mean scores than children in the placebo group; H2.1. Burdon Attention Test mean scores are higher. H2.2. Westside Exam Anxiety mean scores are lower. H3: Children given lavender aroma with an aromatherapy diffuser have lower Westside Exam Anxiety mean scores than children given lemon aroma; H3.1. Westside Exam Anxiety mean scores are lower. H3.2. Burdon Attention Test mean scores are higher.",[629,630,631,632,29],"Aromatherapy","Test Anxiety","Attention Deficits","Academic Achievement",[29,630,634,632,629],"Attention Deficit","2025-01-19",{"date":637,"type":34},"2025-01-24",{"date":639,"type":23},"2025-02-01",{"date":641,"type":23},"2025-09-01",{"name":71,"class":41},{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":18,"minAge":579,"maxAge":334,"enrollmentInfo":650,"targetDuration":4,"studyType":117,"phases":652,"briefSummary":653,"conditions":654,"keywords":659,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":42},"100540097","the-via-family-20---a-family-based-intervention-for-families-with-parental-mental-illness-100540097","NCT06312410","The VIA Family 2.0 - a Family Based Intervention for Families with Parental Mental Illness","The VIA Family 2.0 Study: a Randomized Clinical Trial Evaluating Family-based Interventions for Children Born to Parents with Mental Disorders","Inclusion Criteria:\n\n* At least one of the parents must be living in Capital Region or in Region North, Denmark, and at least one biological child under age 18 must be living with one of the parents. Only biological children of the parent with at mental health problem can be included.\n* The parent with the mental health problems has at some point been diagnosed in the secondary sector and has within the last three years been treated in the primary sector (GP or private psychiatric clinic) or in the secondary sector (hospital psychiatry).\n* Patients with substance abuse can only be included if substance abuse is a secondary diagnosis to another mental illness disorder being treated within the secondary sector during the last three years.\n* All adult participants must give informed consent. Both parents will need to consent in case of shared custody, but do not have to participate if they are reluctant to do so.\n\nExclusion Criteria:\n\n* Not fulfilling inclusion criteria\n* Not giving informed consent\n* Living at Læsø or at Bornholm, Denmark\n* Children placed in care outside of the home fulltime in institution of professional family care (the family is not excluded if the children placed in part time in care outside home or fulltime family care within the family)\n* No risk factors found after baseline assessment (as described in the stepped care model) at baseline - these families can be re-referred if their situation changes.\n* Ongoing intensive family treatment in the municipality (for example staying at an institution for parental evaluation by the authorities)?",{"count":651,"type":23},1452,[142],"VIA Family 2.0 - a Family Based Intervention for families with parental mental illness\n\nBackground: Children born to parents with mental illness have consistently been shown to have increased risks for a range of negative life outcomes including increased frequencies of mental disorders, somatic disorders, poorer cognitive functioning, social, emotional and behavioral problems and lower quality of life. Further these children are often overlooked by both society and mental health services, although they represent a potential for prevention and early intervention.\n\nA collaboration between researchers and clinicians from two regions, the Capital Region and the North Region Denmark has been established as the Research Center for Family Based Interventions. The research center is an umbrella for a series of research activities, all focusing on children and adolescents in families with parental mental illness.\n\nMethod: A large randomized, controlled trial (RCT) for families with parental mental illness will be conducted in order to evaluate the effect of a two-year multidisciplinary, holistic team intervention (the VIA Family 2.0 team intervention) against treatment as usual (TAU). Inclusion criteria will be biological children 0-17 of parents with any mental disorder treated in the secondary sector at any time of their life and receiving treatment in primary or secondary sector within the previous three years. A total of 870 children or approx. 600 families will be included from two sites. Primary outcomes will be changes in child well being, parental stress, family functioning and quality of the home environment, .\n\nTime plan: The RCT will start including families from March 1st, 2024 to Dec 2025 (or later if needed). All families will be assessed at baseline and at end of treatment, i.e. after 24 months and after 36 months. Baseline data will inform the intervention team about each family's needs, problems, and motivation. TAU will be similar in the two regions, which means three family meetings and option for children to participate in peer groups.\n\nChallenges: final funding is being applied for. Recruitment of families can be challenging but we have decades of experience in conducting research in the field. Since both the target group, their potential problems and the intervention is complex, primary outcome is difficult to determine.",[29,655,656,657,658],"Parents","Mental Disorder","Child of Impaired Parents","Preventive Health Services",[660,661,662,663,664],"family based intervention","early intervention","familial high risk","COPMI - children of parents with mental illness","parental mental illness","2024-10-23",{"date":667,"type":34},"2024-10-26",{"date":669,"type":34},"2024-03-18",{"date":671,"type":23},"2028-12-31",{"name":673,"class":41},"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital",{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":678,"acronym":4,"eligibilityCriteria":679,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":384,"enrollmentInfo":680,"targetDuration":4,"studyType":117,"phases":682,"briefSummary":683,"conditions":684,"keywords":691,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":695,"lastUpdatePostDateStruct":696,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":702,"locationsCount":42},"100566498","the-effect-of-gardening-activities-on-anxiety-and-psychosocial-symptoms-of-hospitalized-children-100566498","NCT06655961","The Effect of Gardening Activities on Anxiety and Psychosocial Symptoms of Hospitalized Children","Inclusion Criteria:\n\n* The age of the children is between 6-12 years old\n* Hospitalization due to an acute medical diagnosis\n* Hospitalization for at least 3 days\n* Approval of the child's participation in the session by the responsible doctor\n* The child is conscious and fully orientated\n* Voluntariness of the child and parent to participate in the study\n\nExclusion Criteria:\n\n* Hospitalization for more than 7 days\n* No previous hospitalization experience\n* High-risk drug use\n* Having a chronic disease that suppresses the immune system\n* Having a special condition that prevents him\u002Fher from participating in garden activities (physical, mental disability)\n* Having skin conditions that prevent them from participating in garden activities\n* Plant allergy",{"count":681,"type":23},36,[142],"The experience of hospitalization in childhood can often lead to traumatic consequences. Various practices (play, art therapy, music therapy, etc.) are used to help children cope with this process. In recent years, attention has been drawn to nature-based approaches in addition to existing practices. Within the scope of this approach, this study was planned in a parallel group (experimental-control) randomized controlled experimental design to determine the effect of garden activities on anxiety levels and psychosocial symptoms of hospitalized children aged 6-12 years. Hypotheses of the study H1: The gardening activities program applied to hospitalized children; H1a: There is an effect on children's anxiety. H1b: There is an effect on psychosocial symptoms of children. In this direction, the population of the study will consist of children between the ages of 6-12 in the children's ward of University Research and Application Hospital. The sample size determined as a result of G\\*power analysis was found as control (18) and intervention (18). The research will be conducted between September 2024 and June 2025. 'Child Descriptive Information Form', \"Child Follow-up Form\", \"Child Anxiety Scale-Conditioning\" and \"Psychosocial Symptoms Diagnostic Scale for Hospitalized Children\" will be used for data collection. The data collection process consists of three stages: pre-intervention period, intervention period and post-intervention period. Children in the intervention group will have three sessions of gardening activities within the scope of the 'Gardening Activities Program' during their hospitalization. Children in the control group will receive services within the scope of the routine treatment and nursing care protocol of the clinic during hospitalization.",[685,686,687,688,391,689,29,690],"Gardening","Pediatric Nursing","Activity","Psychosocial Symptoms","Hospital","Investigation of Anxiety Levels and Psychosocial Symptoms of Children Hospitalized for Acute Diseases During Their Hospital Stay",[692,693,686,688,391,694],"Hospitalized Child","Garden Activity","Mobile Garden","2024-10-22",{"date":697,"type":34},"2024-10-24",{"date":699,"type":23},"2024-12",{"date":701,"type":23},"2025-09",{"name":703,"class":41},"Tokat Gaziosmanpasa University",{"id":705,"slug":706,"hasResults":12,"nctId":707,"briefTitle":708,"officialTitle":709,"acronym":710,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":712,"minAge":79,"maxAge":4,"enrollmentInfo":713,"targetDuration":4,"studyType":117,"phases":715,"briefSummary":716,"conditions":717,"keywords":722,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":728,"lastUpdatePostDateStruct":729,"startDateStruct":731,"completionDateStruct":733,"leadSponsor":734,"locationsCount":736},"100540729","phase-4-pharmacokinetic-guided-dosing-of-emicizumab-100540729","NCT06320626","Pharmacokinetic-guided Dosing of Emicizumab","Pharmacokinetic-guided Dosing of Emicizumab in Congenital Haemophilia A Patients - The DosEmi Study","DosEmi","Inclusion Criteria:\n\n* Confirmed diagnosis of congenital haemophilia A, with a baseline endogenous FVIII of \\\u003C6 IU\u002Fml\n* Aged \\> 1 year at inclusion (inclusion of children 1-16 years after favourable interim-analysis see protocol)\n* Receiving conventional dosing of emicizumab (6 mg\u002Fkg\u002F4 weeks with varying intervals) for a duration of at least 12 months prior to inclusion;\n* Having good bleeding control, defined as:\n\ni No spontaneous joint\u002Fmuscle bleeds in the previous 6 months AND ii A maximum of two treated (traumatic) bleeds in the previous 6 months.\n\n* Willing and able to provide written informed consent, either by the subject or its parents\u002Flegal guardian\n* Willing to provide bleeding assessment information\n* Willing to adhere to the medication regimen\n\nExclusion Criteria:\n\n* Acquired haemophilia A","MALE",{"count":714,"type":23},95,[119],"The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.",[718,719,720,123,29,721],"Hemophilia A With Inhibitor","Hemophilia A Without Inhibitor","Hemophilia A, Severe","Adult",[723,724,725,726,727],"Emicizumab","Hemophilia A","Monoclonal antibodies","PK-guided dosing","Hemorrhage","2024-03-12",{"date":730,"type":34},"2024-03-20",{"date":732,"type":34},"2022-09-08",{"date":402,"type":23},{"name":735,"class":41},"Kathelijn Fischer",8]